Filing Flows › Intellia Therapeutics (NTLA) › Q4 2025
Intellia Therapeutics (NTLA) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 26, 2026
Intellia Therapeutics (NTLA) reported revenue of $23.0M for the fourth quarter 2025 (Q4 2025), +79% from a year earlier and +67% from the quarter before. Operating margin was -428.9%, net loss $95.8M (416.2% of revenue).
Intellia Therapeutics, Q4 2025: revenue $23.0M (+79% year over year), operating margin -428.9%, net loss $95.8M, operating cash flow −$69.3M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $23.0M | +67% | +79% |
| Operating profit | −$98.7M | — | — |
| Net earnings | −$95.8M | — | — |
| Operating cash flow | −$69.3M | — | — |
What changed
Revenue was $23.0M in Q4 2025, up 79% year over year and up 67% from the previous quarter.
Operating costs exceeded revenue by $98.7M, an operating margin of -428.9%. Total costs fell 18% while revenue rose 79%. The quarter ended with a net loss of $95.8M, narrower than the previous quarter's $101.3M loss.
Operating cash flow was −$69.3M. Non-cash charges added back $2.4M of depreciation and amortization and $16.7M of share-based compensation. Working capital and other items added $7.4M. Capital expenditures of $126K exceeded it, leaving free cash flow of −$69.4M.
Questions
What was Intellia Therapeutics' revenue in the fourth quarter 2025?
Intellia Therapeutics (NTLA) reported revenue of $23.0M for the fourth quarter 2025 (Q4 2025), +79% from a year earlier and +67% from the quarter before.
Was Intellia Therapeutics profitable in the fourth quarter 2025?
Operating loss was $98.7M (-428.9% of revenue) and net loss $95.8M.